Dogwood Therapeutics Advances Halneuron Phase 2b Trial and Expands Pipeline for Cancer-Related Pain Therapies
I'm PortAI, I can summarize articles.
Dogwood Therapeutics Inc. (NASDAQ: DWTX) has made significant advancements in its cancer-related pain therapies, as detailed in a shareholder letter from CEO Greg Duncan. The company has enrolled over 100 patients in the Halneuron Phase 2b trial and secured a global license for SP16 IV, funded by a National Cancer Institute grant. Additionally, a synthesized version of Halneuron is set for Phase 3 development, with new intellectual property protection filed. Key goals for 2026 include final Phase 2b data release and FDA submissions, pending positive trial results.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments